company background image
IDHC

Integrated Diagnostics Holdings LSE:IDHC Stock Report

Last Price

US$0.77

Market Cap

US$463.8m

7D

1.7%

1Y

-35.4%

Updated

03 Oct, 2022

Data

Company Financials +
IDHC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health4/6
Dividends2/6

IDHC Stock Overview

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients.

Integrated Diagnostics Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Integrated Diagnostics Holdings
Historical stock prices
Current Share PriceUS$0.77
52 Week HighUS$1.45
52 Week LowUS$0.66
Beta0.65
1 Month Change-7.09%
3 Month Change4.46%
1 Year Change-35.45%
3 Year Change-33.65%
5 Year Change-19.69%
Change since IPO-44.79%

Recent News & Updates

Sep 06
Does Integrated Diagnostics Holdings (LON:IDHC) Have A Healthy Balance Sheet?

Does Integrated Diagnostics Holdings (LON:IDHC) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

IDHCGB HealthcareGB Market
7D1.7%-0.3%-1.4%
1Y-35.4%2.7%-14.4%

Return vs Industry: IDHC underperformed the UK Healthcare industry which returned 1.4% over the past year.

Return vs Market: IDHC underperformed the UK Market which returned -15.2% over the past year.

Price Volatility

Is IDHC's price volatile compared to industry and market?
IDHC volatility
IDHC Average Weekly Movement9.1%
Healthcare Industry Average Movement4.0%
Market Average Movement5.5%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.9%

Stable Share Price: IDHC is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IDHC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
19796,388Hend El Sherbinihttps://www.idhcorp.com

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria.

Integrated Diagnostics Holdings Fundamentals Summary

How do Integrated Diagnostics Holdings's earnings and revenue compare to its market cap?
IDHC fundamental statistics
Market CapUS$463.80m
Earnings (TTM)US$60.57m
Revenue (TTM)US$248.99m

7.7x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDHC income statement (TTM)
Revenueج.م4.89b
Cost of Revenueج.م2.55b
Gross Profitج.م2.33b
Other Expensesج.م1.14b
Earningsج.م1.19b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.98
Gross Margin47.70%
Net Profit Margin24.32%
Debt/Equity Ratio4.4%

How did IDHC perform over the long term?

See historical performance and comparison

Dividends

14.5%

Current Dividend Yield

110%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is IDHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDHC?

Other financial metrics that can be useful for relative valuation.

IDHC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA4.1x
PEG Ratio0.4x

Price to Earnings Ratio vs Peers

How does IDHC's PE Ratio compare to its peers?

IDHC PE Ratio vs Peers
The above table shows the PE ratio for IDHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.9x
MGP Medica Group
22.7x16.5%UK£164.1m
SBI Sourcebio International
13.9xn/aUK£92.7m
TLY Totally
53.4x44.3%UK£57.6m
MDMG MD Medical Group Investments
5.8xn/aUS$428.2m
IDHC Integrated Diagnostics Holdings
7.7x18.3%US$463.8m

Price-To-Earnings vs Peers: IDHC is good value based on its Price-To-Earnings Ratio (7.7x) compared to the peer average (23.9x).


Price to Earnings Ratio vs Industry

How does IDHC's PE Ratio compare vs other companies in the European Healthcare Industry?

Price-To-Earnings vs Industry: IDHC is good value based on its Price-To-Earnings Ratio (7.7x) compared to the European Healthcare industry average (14x)


Price to Earnings Ratio vs Fair Ratio

What is IDHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.7x
Fair PE Ratio31.8x

Price-To-Earnings vs Fair Ratio: IDHC is good value based on its Price-To-Earnings Ratio (7.7x) compared to the estimated Fair Price-To-Earnings Ratio (31.8x).


Share Price vs Fair Value

What is the Fair Price of IDHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDHC ($0.77) is trading below our estimate of fair value ($3.29)

Significantly Below Fair Value: IDHC is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Integrated Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDHC's forecast earnings growth (18.3% per year) is above the savings rate (0.9%).

Earnings vs Market: IDHC's earnings (18.3% per year) are forecast to grow faster than the UK market (8.8% per year).

High Growth Earnings: IDHC's earnings are forecast to grow, but not significantly.

Revenue vs Market: IDHC's revenue (11.9% per year) is forecast to grow faster than the UK market (4.4% per year).

High Growth Revenue: IDHC's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDHC's Return on Equity is forecast to be very high in 3 years time (61.1%).


Discover growth companies

Past Performance

How has Integrated Diagnostics Holdings performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


30.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDHC has high quality earnings.

Growing Profit Margin: IDHC's current net profit margins (24.3%) are lower than last year (26.5%).


Past Earnings Growth Analysis

Earnings Trend: IDHC's earnings have grown significantly by 30.1% per year over the past 5 years.

Accelerating Growth: IDHC's earnings growth over the past year (11.9%) is below its 5-year average (30.1% per year).

Earnings vs Industry: IDHC earnings growth over the past year (11.9%) underperformed the Healthcare industry 22.5%.


Return on Equity

High ROE: IDHC's Return on Equity (65.1%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Integrated Diagnostics Holdings's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IDHC's short term assets (EGP2.9B) do not cover its short term liabilities (EGP3.2B).

Long Term Liabilities: IDHC's short term assets (EGP2.9B) exceed its long term liabilities (EGP1.1B).


Debt to Equity History and Analysis

Debt Level: IDHC has more cash than its total debt.

Reducing Debt: IDHC's debt to equity ratio has increased from 2.5% to 4.4% over the past 5 years.

Debt Coverage: IDHC's debt is well covered by operating cash flow (1694.8%).

Interest Coverage: IDHC earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


14.47%

Current Dividend Yield

Dividend Yield vs Market

Integrated Diagnostics Holdings Dividend Yield vs Market
How does Integrated Diagnostics Holdings dividend yield compare to the market?
SegmentDividend Yield
Company (Integrated Diagnostics Holdings)14.5%
Market Bottom 25% (GB)2.1%
Market Top 25% (GB)6.0%
Industry Average (Healthcare)2.3%
Analyst forecast in 3 Years (Integrated Diagnostics Holdings)9.9%

Notable Dividend: IDHC's dividend (14.47%) is higher than the bottom 25% of dividend payers in the UK market (2.11%).

High Dividend: IDHC's dividend (14.47%) is in the top 25% of dividend payers in the UK market (6.08%)


Stability and Growth of Payments

Stable Dividend: IDHC has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: IDHC's dividend payments have increased, but the company has only paid a dividend for 7 years.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (109.6%), IDHC's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (117.9%), IDHC's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average board tenure


CEO

Hend El Sherbini (53 yo)

7.83yrs

Tenure

ج.م8,945,102

Compensation

Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th...


CEO Compensation Analysis

Hend El Sherbini's Compensation vs Integrated Diagnostics Holdings Earnings
How has Hend El Sherbini's remuneration changed compared to Integrated Diagnostics Holdings's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

ج.م1b

Mar 31 2022n/an/a

ج.م1b

Dec 31 2021ج.م9mج.م8m

ج.م1b

Sep 30 2021n/an/a

ج.م1b

Jun 30 2021n/an/a

ج.م1b

Mar 31 2021n/an/a

ج.م816m

Dec 31 2020ج.م9mج.م9m

ج.م594m

Sep 30 2020n/an/a

ج.م523m

Jun 30 2020n/an/a

ج.م466m

Mar 31 2020n/an/a

ج.م491m

Dec 31 2019ج.م9mج.م9m

ج.م511m

Sep 30 2019n/an/a

ج.م508m

Jun 30 2019n/an/a

ج.م510m

Mar 31 2019n/an/a

ج.م518m

Dec 31 2018ج.م8mج.م8m

ج.م502m

Sep 30 2018n/an/a

ج.م447m

Jun 30 2018n/an/a

ج.م435m

Mar 31 2018n/an/a

ج.م405m

Dec 31 2017ج.م4mج.م4m

ج.م374m

Sep 30 2017n/an/a

ج.م343m

Jun 30 2017n/an/a

ج.م292m

Mar 31 2017n/an/a

ج.م276m

Dec 31 2016ج.م4mج.م4m

ج.م260m

Sep 30 2016n/an/a

ج.م247m

Jun 30 2016n/an/a

ج.م251m

Mar 31 2016n/an/a

ج.م198m

Dec 31 2015ج.م4mج.م3m

ج.م145m

Compensation vs Market: Hend's total compensation ($USD455.88K) is below average for companies of similar size in the UK market ($USD1.09M).

Compensation vs Earnings: Hend's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: IDHC's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IDHC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

LSE:IDHC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Aug 22BuyUS$454,607Hend El SherbiniIndividual454,607US$1.00
10 Aug 22BuyUS$4,625Hend El SherbiniIndividual5,000US$0.93
02 Aug 22BuyUS$4,430Hend El SherbiniIndividual5,274US$0.84
29 Jul 22BuyUS$4,025Hend El SherbiniIndividual5,000US$0.81

Ownership Breakdown

What is the ownership structure of IDHC?
Owner TypeNumber of SharesOwnership Percentage
General Public77,455,26512.9%
VC/PE Firms126,000,00021.0%
Individual Insiders153,787,66725.6%
Institutions242,757,06840.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 86.17% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
25.63%
Hend El Sherbini
153,787,667EGP118.9m0.53%no data
21%
Actis LLP
126,000,000EGP97.4m0%55.59%
7.04%
HSBC Global Asset Management (UK) Limited
42,224,558EGP32.6m0%0.03%
4.74%
International Finance Corporation
28,456,384EGP22.0m0%1.83%
4.41%
FMR LLC
26,451,142EGP20.4m0%no data
3.99%
T. Rowe Price Group, Inc.
23,946,015EGP18.5m0%no data
3.37%
Tana Africa Investment Managers Ltd.
20,215,360EGP15.6m0%no data
3.1%
Russell Investment Management, LLC
18,583,000EGP14.4m0%0.02%
3.02%
Norges Bank Investment Management
18,127,918EGP14.0m0%no data
1.77%
Fundsmith, LLP
10,647,023EGP8.2m0.09%0.03%
1.29%
Jupiter Fund Management Plc
7,720,196EGP6.0m0%0.02%
1.08%
RBC Global Asset Management Inc.
6,451,312EGP5.0m4.72%no data
1.05%
Invesco Ltd.
6,300,100EGP4.9m0%no data
0.97%
Harding Loevner LP
5,801,072EGP4.5m0%0.01%
0.57%
Cullen Capital Management, LLC
3,403,550EGP2.6m0%0.03%
0.52%
Franklin Resources, Inc.
3,122,552EGP2.4m-26.25%no data
0.5%
Sanlam Investment Management (Pty) Ltd.
3,000,000EGP2.3m0%0.03%
0.46%
Mazi Asset Management (Pty) Ltd
2,738,380EGP2.1m0%1.4%
0.39%
First Sentier Investors (Australia) IM Ltd
2,359,479EGP1.8m0%no data
0.26%
Dimensional Fund Advisors LP
1,565,834EGP1.2m0.01%no data
0.24%
Grandeur Peak Global Advisors, LLC
1,419,017EGP1.1m-51.13%0.03%
0.22%
Handelsbanken Asset Management
1,316,484EGP1.0m0%no data
0.21%
BlackRock, Inc.
1,277,103EGP987.2k0%no data
0.17%
Danske Capital AS
1,045,600EGP808.2k-7.93%0.01%
0.17%
TRUSTUS Capital Management B.V.
1,032,959EGP798.5k16.78%0.72%

Company Information

Integrated Diagnostics Holdings plc's employee growth, exchange listings and data sources


Key Information

  • Name: Integrated Diagnostics Holdings plc
  • Ticker: IDHC
  • Exchange: LSE
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$463.800m
  • Shares outstanding: 600.00m
  • Website: https://www.idhcorp.com

Number of Employees


Location

  • Integrated Diagnostics Holdings plc
  • 12 Castle Street
  • Saint Helier
  • JE2 3RT
  • Jersey


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDHCLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2015
IDHCLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBUSDMay 2015
IDGX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2015
8I8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2015
IDHCCASE (Cairo and Alexandria Stock Exchange)EGP3.94EGEGPJun 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.